July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Title: Soluble oligomeric Amyloid-β induced retinal pigment epithelial degeneration requires non-canonical inflammsome activation
Author Affiliations & Notes
  • Siddharth Narendran
    Department of Ophthalmology, University of Virginia, Charlottesville, Virginia, United States
  • DAIPAYAN BANERJEE
    Department of Ophthalmology, University of Virginia, Charlottesville, Virginia, United States
  • Ivana Apicella
    Department of Ophthalmology, University of Virginia, Charlottesville, Virginia, United States
  • Shaobin Wang
    Department of Ophthalmology, University of Virginia, Charlottesville, Virginia, United States
  • Akhil Varshney
    Department of Ophthalmology, University of Virginia, Charlottesville, Virginia, United States
  • Shinichi Fukuda
    Department of Ophthalmology, University of Virginia, Charlottesville, Virginia, United States
  • Nagaraj Kerur
    Department of Ophthalmology, University of Virginia, Charlottesville, Virginia, United States
  • Bradley Gelfand
    Department of Ophthalmology, University of Virginia, Charlottesville, Virginia, United States
  • Jayakrishna Ambati
    Department of Ophthalmology, University of Virginia, Charlottesville, Virginia, United States
  • Footnotes
    Commercial Relationships   Siddharth Narendran, None; DAIPAYAN BANERJEE, None; Ivana Apicella, None; Shaobin Wang, None; Akhil Varshney, None; Shinichi Fukuda, None; Nagaraj Kerur, University of Virginia (P); Bradley Gelfand, University of Virginia (P); Jayakrishna Ambati, Allergan (C), Allergan (R), Boehringer-Ingelheim (C), Inflammasome Therapeutics (I), Inflammasome Therapeutics (P), Inflammasome Therapeutics (S), iVeena (I), iVeena (P), iVeena (S), Janssen (C), Janssen (R), OliXPharmaceuticals (C), Retinal Solutions (C), SaksinLifesciences (C)
  • Footnotes
    Support  NEI/NIH; NIGMS/NIH; John Templeton Foundation
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 990. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Siddharth Narendran, DAIPAYAN BANERJEE, Ivana Apicella, Shaobin Wang, Akhil Varshney, Shinichi Fukuda, Nagaraj Kerur, Bradley Gelfand, Jayakrishna Ambati; Title: Soluble oligomeric Amyloid-β induced retinal pigment epithelial degeneration requires non-canonical inflammsome activation. Invest. Ophthalmol. Vis. Sci. 2019;60(9):990. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Purpose:
Amyloid-β (Aβ) is a component of drusen in macular degeneration. Although several studies have established the role of Aβ in the development and progression of RPE degeneration, the mechanism of Aβ-induced cell death is still unclear. We hypothesize that soluble oligomeric forms of Aβ induced RPE degeneration requires the activation of the non-canonical inflammasome pathway.

Methods : Methods:
Oligomeric Aβ was prepared using established protocols. Wild-type (WT) C57BL/6J, Ppif−/−, Gsdmd−/−, Casp11−/− and cGAS−/− mice received subretinal injections of Aβ1-40 or Aβ40-1. RPE degeneration was assessed by fundus photography and Zonula occludens-1 (ZO-1) staining of RPE flat mounts. Primary human RPE cells in culture were exposed to oligomerized Aβ1-40. Non-canonical Inflammasome activation was monitored by immunoblotting for caspase-1 and caspase-4/11 and quantitative real-time RT-PCR for NLRP3, Gasdermin-D and IL-18

Results : Results:
Subretinal injection of oligomerized Aβ1-40 peptide induced RPE degeneration in WT but not in Ppif−/−, Gsdmd−/−, Casp11−/− or cGAS−/− mice. Oligomerized Aβ1-40 treatment of RPE cells caused activation of Caspase-1 and caspase-4 and induction of Gasdermin-D, IL-18 and NLRP3.

Conclusions : Conclusion:
Our findings reveal the role of the non-canonical imflammsome pathway in Aβ-induced RPE degeneration that could provide potential novel pharmacological targets for the treatment of Geographic Atrophy.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×